Alpha Centric Advisors LLC Ventyx Biosciences, Inc. Transaction History
Alpha Centric Advisors LLC
- $121 Million
- Q2 2024
A detailed history of Alpha Centric Advisors LLC transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 10,000 shares of VTYX stock, worth $20,600. This represents 0.02% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$20,600
Previous $55,000
58.18%
% of portfolio
0.02%
Previous 0.04%
Shares
2 transactions
Others Institutions Holding VTYX
# of Institutions
124Shares Held
57.4MCall Options Held
222KPut Options Held
269K-
Deerfield Management Company, L.P. (Series C) New York, NY5.83MShares$12 Million0.28% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il5.76MShares$11.9 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA5.25MShares$10.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$9.83 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.17MShares$6.53 Million0.04% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $116M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...